<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03131583</url>
  </required_header>
  <id_info>
    <org_study_id>SHR4640-103</org_study_id>
    <nct_id>NCT03131583</nct_id>
  </id_info>
  <brief_title>The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout</brief_title>
  <official_title>A Phase I, Single-Center, Open-Label, Single-Group Study to Evaluate Potential Pharmacodynamics of Drug-Drug Interaction Between SHR4640 and Febuxostat and Between SHR4640 and Colchicine in Patients With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the pharmacodynamic properties of drug-drug of
      SHR4640, Febuxostat and Colchicine interaction in patients with gout.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2017</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximun observed concentration (Cmax) of Febuxostat and Colchicine from plasma</measure>
    <time_frame>Clinical significant changes from baseline up to Day 8</time_frame>
    <description>PK profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) of Febuxostat and Colchicine from plasma</measure>
    <time_frame>Clinical significant changes from baseline up to Day 8</time_frame>
    <description>PK profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal half-life (t1/2) of Febuxostat and Colchicine from plasma</measure>
    <time_frame>Clinical significant changes from baseline up to Day 8</time_frame>
    <description>PK profile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse events</measure>
    <time_frame>Clinical significant changes from Day-14 up to Day 16</time_frame>
    <description>Safety issue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Laboratory Values</measure>
    <time_frame>Clinical significant changes from Day-14 up to Day 16</time_frame>
    <description>Safety issue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Electrocardiogram</measure>
    <time_frame>Clinical significant changes from Day-14 up to Day 16</time_frame>
    <description>Safety issue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Vital Signs Parameters</measure>
    <time_frame>Clinical significant changes from Day-14 up to Day 16</time_frame>
    <description>Safety issue</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine 0.5 mg Oral Tablet Day-14~Day16 qd, Febuxostat 80 mg Oral Tablet Day1 and Day8 qd, SHR4640 10 mg Oral Tablet Day3~Day8 qd.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Day-14~Day16 qd</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Day1 and Day8 qd</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR4640</intervention_name>
    <description>Day3~Day8 qd</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has a body mass index ≥18.5 and ≤30 kg/m2;

          2. Screening sUA value ≥8 and ≤10 mg/dl;

          3. Subject has no clinically relevant abnormalities in vital signs, ECG, physical
             examination，imaging examination or safety laboratory values.

        Exclusion Criteria:

          1. Subject known or suspected of being sensitive to the study drugs or its ingredient；

          2. sCr&gt;ULN;

          3. History of kidney stones or screening kidney stones by B-ultrasound；

          4. History of malignancy within 5 years；

          5. History of xanthinuria；

          6. Donated blood（≥400ml）within 3 months prior to screening or received transfusion of
             blood。
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liyan Miao</last_name>
    <phone>18915505252</phone>
    <email>miaolysuzhou@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liyan Miao</last_name>
      <phone>18915505252</phone>
      <email>miaolysuzhou@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHR4640 Febuxostat Colchicine pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

